| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Lauroyl-L-carnitine-d9 chloride does not have a specific biological target as a drug; it is a stable isotope-labeled compound. The deuterium atoms are incorporated into the three N-methyl groups. The compound is used as a tracer to study lipid metabolism, mitochondrial function, and the role of carnitine in cellular energy production.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may affect a drug's pharmacokinetics and metabolic properties, it is a cause for concern [75].
Lauroyl-L-carnitine-d9 chloride is not evaluated for in vitro biological activity as a drug; it is a stable isotope-labeled tracer. The labeled version is used for analytical and metabolic studies and does not have intrinsic pharmacological activity. |
| ln Vivo |
Lauroyl-L-carnitine-d9 chloride is not administered as a therapeutic agent and does not have intrinsic in vivo pharmacological activity. It is used as a tracer in metabolic studies to track fatty acid transport and metabolism.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for Lauroyl-L-carnitine-d9 chloride as a drug target. As a labeled compound, it is used in metabolic studies. The compound is characterized by its isotopic purity.
|
| Cell Assay |
In vitro cellular assays for Lauroyl-L-carnitine-d9 chloride involve its use in cell culture to study fatty acid metabolism. Cells are treated with the labeled compound, and its incorporation into metabolic pathways is tracked by mass spectrometry.
|
| Animal Protocol |
In vivo animal studies with Lauroyl-L-carnitine-d9 chloride involve its administration to animals to study fatty acid metabolism and distribution. The compound is used as a tracer, and its levels in tissues and biological fluids are measured by mass spectrometry.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Lauroyl-L-carnitine-d9 chloride are not studied as a drug; it is a metabolic tracer. The labeled compound has similar properties to lauroyl-L-carnitine. It is typically used in trace amounts for analytical purposes.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Lauroyl-L-carnitine-d9 chloride is not reported, as it is a stable isotope-labeled research compound used in trace amounts. Carnitine derivatives are generally considered safe. The labeled version is not used for therapeutic purposes.
|
| References | |
| Additional Infomation |
Lauroyl-L-carnitine-d9 chloride is a deuterium-labeled form of lauroyl-L-carnitine used as a tracer in metabolic studies of fatty acid transport and mitochondrial function. It has a molecular weight of 389.02. The compound is available for research purposes only.
|
| Molecular Formula |
C19H38CLNO4
|
|---|---|
| Molecular Weight |
379.96
|
| Exact Mass |
388.305
|
| CAS # |
2245711-25-3
|
| Related CAS # |
Lauroyl-L-carnitine chloride;6919-91-1;Lauroyl-L-carnitine-d3 hydrochloride;1297271-52-3
|
| PubChem CID |
163408768
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
25
|
| Complexity |
350
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[C@@H](CC(=O)O)(C[N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])OC(=O)CCCCCCCCCCC.[Cl-]
|
| InChi Key |
PDBBUDRTWRVCFN-KIYCHUIWSA-N
|
| InChi Code |
InChI=1S/C19H37NO4.ClH/c1-5-6-7-8-9-10-11-12-13-14-19(23)24-17(15-18(21)22)16-20(2,3)4;/h17H,5-16H2,1-4H3;1H/t17-;/m1./s1/i2D3,3D3,4D3;
|
| Chemical Name |
[(2R)-3-carboxy-2-dodecanoyloxypropyl]-tris(trideuteriomethyl)azanium;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6319 mL | 13.1593 mL | 26.3186 mL | |
| 5 mM | 0.5264 mL | 2.6319 mL | 5.2637 mL | |
| 10 mM | 0.2632 mL | 1.3159 mL | 2.6319 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
